Holmes, F A <br/><br/>
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 1999 
 - 403-11 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1023/a:1008360406322  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor--analysis<br/>Bone Neoplasms--secondary<br/>Breast Neoplasms--diagnosis<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Heart Diseases--chemically induced<br/>Humans<br/>Infusions, Intravenous<br/>Lung Neoplasms--secondary<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Paclitaxel--administration & dosage<br/>Severity of Illness Index<br/>Soft Tissue Neoplasms--secondary<br/>Survival Rate<br/>Treatment Outcome